Publication | Closed Access

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

OncologyPembrolizumab Versus PlaceboMelanomaClinical TrialsMetastatic MelanomaImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentMedicineRadiation OncologyPhase 3Health Sciences